KALA
KALA BIO, Inc.
There isn't enough reported data to score KALA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
KALA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KALA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KALA PE Valuation
KALA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
KALA Forward outlook
There aren't enough analyst estimates for KALA to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KALA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$204.63 | +$302.87 |
| Q3 2025 | -$252.50 | +$341.50 |
| Q2 2025 | -$295.50 | +$372.50 |
| Q1 2025 | -$368.00 | +$360.00 |
| Q4 2024 | -$507.50 | +$360.00 |
| Q3 2022 | -$2,862.50 | +$2,237.50 |
| Q2 2022 | -$4,900.00 | +$375.00 |
| Q1 2022 | -$5,375.00 | -$475.00 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 140% for KALA versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
KALA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $420K | -86% |
| Q2 2022 | $2.1M | -31% |
| Q1 2022 | $1.4M | -58% |
| Q4 2021 | $1.9M | -17% |
| Q3 2021 | $3.1M | +38% |
| Q2 2021 | $3.1M | +266% |
| Q1 2021 | $3.3M | +205% |
| Q4 2020 | $2.2M | +90% |
OSCR has the stronger quarterly revenue trend. Revenue is down 100% for KALA versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -3469% | -2619 points |
| Q2 2022 | -1237% | -285 points |
| Q1 2022 | -2253% | -1386 points |
| Q4 2021 | -2522% | -1227 points |
| Q3 2021 | -850% | +314 points |
| Q2 2021 | -952% | +1603 points |
| Q1 2021 | -867% | +1012 points |
| Q4 2020 | -1295% | +417 points |
KALA's operating margin was −3469% last quarter, down 2619 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
KALA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | +$15M |
| Q1 2026 | -$2.9M | +$5.9M |
| Q4 2025 | -$4.6M | +$42K |
| Q3 2025 | -$10.9M | -$6.2M |
| Q2 2025 | -$16.6M | -$7.3M |
| Q1 2025 | -$8.8M | +$2M |
| Q4 2024 | -$4.6M | +$3.1M |
| Q3 2024 | -$4.7M | -$1.8M |
KALA has burned cash in almost every quarter: −$20M over the past year, against −$35M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over KALA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KALA Net Leverage
KALA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
KALA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.7 | Oversold |
KALA's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KALA PE vs Healthcare Sector
KALA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KALA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.25 | 36% below |
| 20 week MA | $0.59 | 73% below |
| 50 week MA | $9.99 | 98% below |
| 100 week MA | $160.4 | 100% below |
| 200 week MA | $321.9 | 100% below |
KALA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over KALA on trend strength, trading above more of its moving averages.
KALA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9,325.0 | $19,150.0 | +105% |
| 2021 | $19,150.0 | $3,400.0 | -82% |
| 2022 | $3,400.0 | $194.0 | -94% |
| 2023 | $194.0 | $350.0 | +80% |
| 2024 | $350.0 | $349.0 | -0.3% |
| 2025 | $349.0 | $32.5 | -91% |
| 2026 YTD | $32.5 | $0.16 | -100% |
KALA's yearly returns have swung widely, from +105% in 2020 to −94% in 2022. It's down 100% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KALA on returns for 2026, with the stronger performance.